Syphilis remains a significant global public health concern, with rising case numbers reported in multiple regions over the past decade. Once nearly eradicated in many high-income countries due to widespread penicillin use, the sexually transmitted infection has seen a troubling resurgence, particularly among men who have sex with men and individuals with limited access to sexual health services. Understanding its symptoms, transmission risks, and the importance of early diagnosis is critical to curbing its spread and preventing long-term complications.
The disease, caused by the bacterium Treponema pallidum, progresses through distinct stages if left untreated, each with characteristic clinical manifestations. While the initial sign is often a painless sore known as a chancre, many people overlook or mistake it for a minor skin irritation, delaying medical attention. This delay increases the risk of progression to secondary and latent stages, where systemic symptoms emerge and the potential for irreversible damage to organs such as the heart and brain grows significantly.
According to the World Health Organization, an estimated 8 million new cases of syphilis occur globally each year, with substantial increases noted in Europe, the Americas, and parts of Asia since 2010. In Germany, the Robert Koch Institute reported a 45% rise in syphilis notifications between 2010 and 2022, reflecting broader trends in Western Europe. These increases are attributed to factors including decreased condom use, rising numbers of sexual partners facilitated by dating apps, and reduced funding for public sexually transmitted infection (STI) screening programs in some regions.
Primary syphilis typically presents as a single, firm, round sore at the site of infection — commonly on the genitals, anus, or mouth — appearing approximately three weeks after exposure. Though painless and often self-resolving within three to six weeks, the chancre is highly infectious. Without treatment, the bacterium disseminates through the bloodstream, leading to secondary syphilis within weeks to months.
Secondary syphilis is marked by a non-itchy rash that commonly appears on the palms of the hands and soles of the feet, though it can spread to the trunk and limbs. Accompanying symptoms may include fever, swollen lymph nodes, sore throat, patchy hair loss, headaches, weight loss, and muscle aches. These signs can be mild and transient, often resolving spontaneously, which further contributes to underdiagnosis. However, the infection remains active and transmissible during this phase.
If untreated, syphilis enters a latent stage, divided into early latent (less than one year since infection) and late latent (more than one year). During latency, no visible symptoms are present, but the bacteria persist in the body. Approximately 15 to 30 percent of individuals with untreated syphilis will eventually develop tertiary syphilis years or even decades later, a severe form capable of causing neurosyphilis, cardiovascular syphilis, or gummatous lesions in bones and soft tissues.
Neurosyphilis, which can occur at any stage but is more common in late disease, may lead to meningitis, stroke-like symptoms, dementia, or impaired coordination. Cardiovascular syphilis can result in aortic aneurysms or valve insufficiency. These complications underscore why timely detection and treatment are essential, even in the absence of noticeable symptoms.
Diagnosis and Testing: Why Early Detection Matters
Diagnosing syphilis relies on a combination of clinical evaluation and laboratory testing, as symptoms alone are not reliable for confirmation. Healthcare providers typically use two types of blood tests: non-treponemal assays (such as RPR or VDRL) that detect antibodies produced in response to infection, and treponemal tests that identify antibodies specific to Treponema pallidum. A positive result on both types is generally required for diagnosis, though algorithms may vary by region.
Testing is recommended for anyone with symptoms suggestive of syphilis, individuals diagnosed with another STI, pregnant people (due to risks of congenital transmission), and those with multiple sexual partners or HIV infection. The Centers for Disease Control and Prevention advises annual syphilis screening for sexually active gay and bisexual men, with more frequent testing (every 3 to 6 months) for those at higher risk based on behavior or local epidemiology.
In prenatal care, syphilis screening is performed early in pregnancy and repeated in the third trimester and at delivery in high-prevalence settings to prevent congenital syphilis, which can cause miscarriage, stillbirth, neonatal death, or severe developmental delays in infants. The World Health Organization emphasizes that benzathine penicillin G remains the gold standard treatment for syphilis at all stages, administered via intramuscular injection. Dosage and duration depend on the disease stage, with neurosyphilis requiring intravenous penicillin for effective central nervous system penetration.
For individuals allergic to penicillin, desensitization protocols under medical supervision are preferred, as alternative antibiotics like doxycycline or azithromycin are less reliably effective and carry higher risks of treatment failure. Partner notification and treatment are critical components of syphilis control to prevent reinfection and further transmission.
Public Health Response and Prevention Strategies
Controlling syphilis resurgence requires a multifaceted approach combining accessible testing, prompt treatment, sexual health education, and efforts to reduce stigma around STI screening. In several European countries, including Germany and the United Kingdom, public health agencies have launched targeted outreach campaigns using social media and dating apps to encourage testing among high-risk populations.
The European Centre for Disease Prevention and Control notes that while condom use remains one of the most effective preventive measures, its inconsistent use — particularly in monogamous-perceived relationships or among individuals using pre-exposure prophylaxis (PrEP) for HIV — has contributed to increased STI transmission. PrEP users are advised to undergo regular STI screening, including for syphilis, as part of comprehensive sexual health monitoring.
Innovations in point-of-care testing are expanding access to rapid syphilis diagnosis in community settings, allowing same-day results and immediate treatment initiation. Some cities have implemented syphilis screening programs in emergency departments, prisons, and mobile clinics to reach underserved groups. However, disparities in access persist, particularly among migrants, transgender individuals, and people experiencing homelessness.
Public health experts stress that syphilis is not a disease of the past but a present-day challenge requiring sustained investment in surveillance, healthcare infrastructure, and community engagement. As Dr. Anna Mayer, an infectious disease specialist at Charité – Universitätsmedizin Berlin, stated in a 2023 interview with Deutsche Welle: “We have the tools to eliminate syphilis — effective antibiotics, reliable diagnostics, and prevention strategies. What we need now is the political will and public health prioritization to deploy them equitably.”
What So for Readers
If you are sexually active, especially with new or multiple partners, incorporating routine STI screening into your healthcare routine is a proactive step toward protecting your long-term health. Many clinics offer confidential, low-cost or free testing, and home collection kits for syphilis and other infections are increasingly available in certain countries through verified public health programs.
Recognizing that early syphilis can mimic benign conditions empowers individuals to seek care when something feels unusual — whether it’s a sore that doesn’t heal, an unexplained rash, or flu-like symptoms after potential exposure. Delaying testing does not make the infection go away; it allows it to progress silently.
Treatment is highly effective when administered correctly, and most people recover fully without complications when diagnosed early. The key is not waiting for symptoms to worsen but acting on awareness and access.
For the most current guidance on syphilis testing, treatment, and prevention, consult official sources such as the World Health Organization’s sexually transmitted infections page, your national public health agency (like the Robert Koch Institute in Germany or the CDC in the United States), or a trusted healthcare provider.
Stay informed, prioritize your sexual health, and consider sharing this information with others who may benefit. We welcome your thoughts and experiences in the comments below — let’s continue the conversation on how communities can strengthen STI prevention and care.